{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-399425","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2026-09-23T20:15:16+00:00","discovered_at":"2026-09-23T20:16:10.721291+00:00","generated_at":"2026-09-23T20:16:23.600925+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Jazz extends $1.9B term loan to 2033, cuts margin by 50 bps","bullets":["Jazz Lux amended credit agreement to extend $1,895,000,000 term loans maturity from May 5, 2028 to May 5, 2033.","Interest margin reduced by 50 bps: now Term SOFR + 1.75% or prime + 0.75%, with 0.50% SOFR floor.","Borrowed $273,310,355.18 new Tranche B-3 loans to repay non-converted Tranche B-2 loans; total principal unchanged at $1,895,000,000.","Loans amortize quarterly at 0.25% of initial principal, balance due at new 2033 maturity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-399425","json":"https://secwatch.observer/filing/0001193125-26-399425.json","markdown":"https://secwatch.observer/filing/0001193125-26-399425.md","text":"https://secwatch.observer/filing/0001193125-26-399425.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000119312526399425/0001193125-26-399425-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000119312526399425/d163027d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-23T20:16:23.600925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}